CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
24 oct. 2024 08h30 HE | Calidi Biotherapeutics, Inc
- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases,...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
23 oct. 2024 08h31 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
30 sept. 2024 08h00 HE | Calidi Biotherapeutics, Inc
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
13 août 2024 17h37 HE | Calidi Biotherapeutics, Inc
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
29 juil. 2024 09h00 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
18 juil. 2024 08h00 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
16 juil. 2024 08h00 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
logo.jpg
Oncolytic Virus Therapy Market Size Clinical Trials Sales Forecast 2030
14 mai 2024 01h08 HE | KuicK Research
Delhi, May 14, 2024 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030 Report Highlights: Global Oncolytic Virus Immunotherapy Therapy...
Imugen.PNG
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
09 avr. 2024 12h00 HE | Imugene Limited
Imugene announced poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Conference.
MustangBioLogo.jpg
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
26 oct. 2023 09h00 HE | Mustang Bio, Inc.
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data...